These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 26690113)
1. Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET Imaging. Bernard-Gauthier V; Bailey JJ; Berke S; Schirrmacher R Molecules; 2015 Dec; 20(12):22000-27. PubMed ID: 26690113 [TBL] [Abstract][Full Text] [Related]
2. Syntheses and evaluation of carbon-11- and fluorine-18-radiolabeled pan-tropomyosin receptor kinase (Trk) inhibitors: exploration of the 4-aza-2-oxindole scaffold as Trk PET imaging agents. Bernard-Gauthier V; Aliaga A; Aliaga A; Boudjemeline M; Hopewell R; Kostikov A; Rosa-Neto P; Thiel A; Schirrmacher R ACS Chem Neurosci; 2015 Feb; 6(2):260-76. PubMed ID: 25350780 [TBL] [Abstract][Full Text] [Related]
3. PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET. Slobbe P; Poot AJ; Windhorst AD; van Dongen GA Drug Discov Today; 2012 Nov; 17(21-22):1175-87. PubMed ID: 22766374 [TBL] [Abstract][Full Text] [Related]
4. [¹¹C]Sorafenib: radiosynthesis and preclinical evaluation in tumor-bearing mice of a new TKI-PET tracer. Poot AJ; van der Wildt B; Stigter-van Walsum M; Rongen M; Schuit RC; Hendrikse NH; Eriksson J; van Dongen GA; Windhorst AD Nucl Med Biol; 2013 May; 40(4):488-97. PubMed ID: 23522977 [TBL] [Abstract][Full Text] [Related]
5. A Kinome-Wide Selective Radiolabeled TrkB/C Inhibitor for in Vitro and in Vivo Neuroimaging: Synthesis, Preclinical Evaluation, and First-in-Human. Bernard-Gauthier V; Bailey JJ; Mossine AV; Lindner S; Vomacka L; Aliaga A; Shao X; Quesada CA; Sherman P; Mahringer A; Kostikov A; Grand'Maison M; Rosa-Neto P; Soucy JP; Thiel A; Kaplan DR; Fricker G; Wängler B; Bartenstein P; Schirrmacher R; Scott PJH J Med Chem; 2017 Aug; 60(16):6897-6910. PubMed ID: 28696690 [TBL] [Abstract][Full Text] [Related]
6. PET imaging for tyrosine kinase inhibitor (TKI) biodistribution in mice. Fushiki H; Murakami Y; Miyoshi S; Nishimura S Methods Mol Biol; 2015; 1219():199-206. PubMed ID: 25308271 [TBL] [Abstract][Full Text] [Related]
7. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. Vallabhajosula S Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348 [TBL] [Abstract][Full Text] [Related]
8. PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET. van Dongen GA; Poot AJ; Vugts DJ Tumour Biol; 2012 Jun; 33(3):607-15. PubMed ID: 22270450 [TBL] [Abstract][Full Text] [Related]
9. Molecular imaging of epidermal growth factor receptor expression-activity at the kinase level in tumors with positron emission tomography. Gelovani JG Cancer Metastasis Rev; 2008 Dec; 27(4):645-53. PubMed ID: 18626573 [TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of a fluorinated quinazoline-based type-II Trk inhibitor as a scaffold for PET radiotracer development. Bernard-Gauthier V; Mahringer A; Vesnaver M; Fricker G; Schirrmacher R Bioorg Med Chem Lett; 2017 Jun; 27(12):2771-2775. PubMed ID: 28476569 [TBL] [Abstract][Full Text] [Related]
11. Some implications of receptor kinase signaling pathway for development of multitargeted kinase inhibitors. Mitrasinovic PM Curr Radiopharm; 2013 Mar; 6(1):48-55. PubMed ID: 23278847 [TBL] [Abstract][Full Text] [Related]
12. Fluorine-18 radiolabeling and radiopharmacological characterization of a benzodioxolylpyrimidine-based radiotracer targeting the receptor tyrosine kinase EphB4. Mamat C; Mosch B; Neuber C; Köckerling M; Bergmann R; Pietzsch J ChemMedChem; 2012 Nov; 7(11):1991-2003. PubMed ID: 23042640 [TBL] [Abstract][Full Text] [Related]
13. A tyrosine kinase inhibitor-based high-affinity PET radiopharmaceutical targets vascular endothelial growth factor receptor. Li F; Jiang S; Zu Y; Lee DY; Li Z J Nucl Med; 2014 Sep; 55(9):1525-31. PubMed ID: 24970912 [TBL] [Abstract][Full Text] [Related]
14. Preclinical in vivo cancer, straightway to patients? de Jong M; Mather S; Maina T Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):145-152. PubMed ID: 28347131 [TBL] [Abstract][Full Text] [Related]
15. Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET. Bahce I; Yaqub M; Smit EF; Lammertsma AA; van Dongen GA; Hendrikse NH Lung Cancer; 2017 May; 107():1-13. PubMed ID: 27319335 [TBL] [Abstract][Full Text] [Related]
16. Two anti-angiogenic TKI-PET tracers, [(11)C]axitinib and [(11)C]nintedanib: Radiosynthesis, in vivo metabolism and initial biodistribution studies in rodents. Slobbe P; Poot AJ; Haumann R; Schuit RC; Windhorst AD; van Dongen GA Nucl Med Biol; 2016 Oct; 43(10):612-24. PubMed ID: 27497236 [TBL] [Abstract][Full Text] [Related]
17. PET probe detecting non-small cell lung cancer susceptible to epidermal growth factor receptor tyrosine kinase inhibitor therapy. Makino A; Miyazaki A; Tomoike A; Kimura H; Arimitsu K; Hirata M; Ohmomo Y; Nishii R; Okazawa H; Kiyono Y; Ono M; Saji H Bioorg Med Chem; 2018 May; 26(8):1609-1613. PubMed ID: 29478801 [TBL] [Abstract][Full Text] [Related]
18. Fluorine-18 Labelled Radioligands for PET Imaging of Cyclooxygenase-2. Kaur J; Bhardwaj A; Wuest F Molecules; 2022 Jun; 27(12):. PubMed ID: 35744851 [TBL] [Abstract][Full Text] [Related]
19. Radiolabeled inorganic nanoparticles for positron emission tomography imaging of cancer: an overview. Chakravarty R; Goel S; Dash A; Cai W Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):181-204. PubMed ID: 28124549 [TBL] [Abstract][Full Text] [Related]
20. Radiolabeled small molecule protein kinase inhibitors for imaging with PET or SPECT. Hicks JW; VanBrocklin HF; Wilson AA; Houle S; Vasdev N Molecules; 2010 Nov; 15(11):8260-78. PubMed ID: 21079565 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]